IMVT
Price
$17.49
Change
+$0.14 (+0.81%)
Updated
Oct 14 closing price
Capitalization
3.05B
16 days until earnings call
Intraday Buy/Sell Signals
SRPT
Price
$21.43
Change
-$0.53 (-2.41%)
Updated
Oct 14 closing price
Capitalization
2.24B
14 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

IMVT vs SRPT

Header iconIMVT vs SRPT Comparison
Open Charts IMVT vs SRPTBanner chart's image
Immunovant
Price$17.49
Change+$0.14 (+0.81%)
Volume$1.88M
Capitalization3.05B
Sarepta Therapeutics
Price$21.43
Change-$0.53 (-2.41%)
Volume$3.75M
Capitalization2.24B
IMVT vs SRPT Comparison Chart in %
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMVT vs. SRPT commentary
Oct 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a Hold and SRPT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 15, 2025
Stock price -- (IMVT: $17.49 vs. SRPT: $21.43)
Brand notoriety: IMVT: Not notable vs. SRPT: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMVT: 116% vs. SRPT: 51%
Market capitalization -- IMVT: $3.05B vs. SRPT: $2.24B
IMVT [@Biotechnology] is valued at $3.05B. SRPT’s [@Biotechnology] market capitalization is $2.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMVT’s FA Score shows that 0 FA rating(s) are green whileSRPT’s FA Score has 0 green FA rating(s).

  • IMVT’s FA Score: 0 green, 5 red.
  • SRPT’s FA Score: 0 green, 5 red.
According to our system of comparison, IMVT is a better buy in the long-term than SRPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMVT’s TA Score shows that 6 TA indicator(s) are bullish while SRPT’s TA Score has 5 bullish TA indicator(s).

  • IMVT’s TA Score: 6 bullish, 3 bearish.
  • SRPT’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, IMVT is a better buy in the short-term than SRPT.

Price Growth

IMVT (@Biotechnology) experienced а +8.57% price change this week, while SRPT (@Biotechnology) price change was -7.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.76%. For the same industry, the average monthly price growth was +13.99%, and the average quarterly price growth was +268.92%.

Reported Earning Dates

IMVT is expected to report earnings on Oct 31, 2025.

SRPT is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+0.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMVT($3.05B) has a higher market cap than SRPT($2.24B). IMVT YTD gains are higher at: -29.390 vs. SRPT (-82.375). SRPT has higher annual earnings (EBITDA): 36.1M vs. IMVT (-470.69M). SRPT has more cash in the bank: 800M vs. IMVT (599M). IMVT has less debt than SRPT: IMVT (98K) vs SRPT (1.35B). SRPT has higher revenues than IMVT: SRPT (2.48B) vs IMVT (0).
IMVTSRPTIMVT / SRPT
Capitalization3.05B2.24B136%
EBITDA-470.69M36.1M-1,304%
Gain YTD-29.390-82.37536%
P/E RatioN/A27.21-
Revenue02.48B-
Total Cash599M800M75%
Total Debt98K1.35B0%
FUNDAMENTALS RATINGS
IMVT vs SRPT: Fundamental Ratings
IMVT
SRPT
OUTLOOK RATING
1..100
718
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
71
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9893
PRICE GROWTH RATING
1..100
6362
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (34) in the null industry is somewhat better than the same rating for SRPT (71) in the Biotechnology industry. This means that IMVT’s stock grew somewhat faster than SRPT’s over the last 12 months.

IMVT's Profit vs Risk Rating (100) in the null industry is in the same range as SRPT (100) in the Biotechnology industry. This means that IMVT’s stock grew similarly to SRPT’s over the last 12 months.

SRPT's SMR Rating (93) in the Biotechnology industry is in the same range as IMVT (98) in the null industry. This means that SRPT’s stock grew similarly to IMVT’s over the last 12 months.

SRPT's Price Growth Rating (62) in the Biotechnology industry is in the same range as IMVT (63) in the null industry. This means that SRPT’s stock grew similarly to IMVT’s over the last 12 months.

SRPT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IMVT (100) in the null industry. This means that SRPT’s stock grew similarly to IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMVTSRPT
RSI
ODDS (%)
N/A
Bearish Trend 8 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 8 days ago
82%
Bearish Trend 8 days ago
75%
Momentum
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 8 days ago
70%
MACD
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 8 days ago
60%
TrendWeek
ODDS (%)
Bearish Trend 8 days ago
84%
Bullish Trend 8 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 8 days ago
84%
Bullish Trend 8 days ago
71%
Advances
ODDS (%)
Bullish Trend 13 days ago
75%
Bullish Trend 10 days ago
75%
Declines
ODDS (%)
Bearish Trend 8 days ago
83%
N/A
BollingerBands
ODDS (%)
Bearish Trend 9 days ago
87%
Bearish Trend 8 days ago
78%
Aroon
ODDS (%)
Bullish Trend 8 days ago
79%
Bearish Trend 8 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GNSRX32.600.44
+1.37%
abrdn US Small Cap Equity R
QUASX65.600.11
+0.17%
AB Small Cap Growth A
GESOX19.020.02
+0.11%
Lazard Global Equity Select Port Open
FZANX51.48N/A
N/A
Fidelity Advisor New Insights Z
BIRIX23.44N/A
N/A
BlackRock Sust Awr Advtg Lg Cp Cr Instl

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
+0.81%
ROIV - IMVT
59%
Loosely correlated
+1.17%
IDYA - IMVT
57%
Loosely correlated
+1.12%
NUVL - IMVT
55%
Loosely correlated
-5.67%
OCUL - IMVT
54%
Loosely correlated
-5.23%
DNLI - IMVT
54%
Loosely correlated
+1.54%
More

SRPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRPT has been loosely correlated with BPMUF. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if SRPT jumps, then BPMUF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRPT
1D Price
Change %
SRPT100%
-2.41%
BPMUF - SRPT
52%
Loosely correlated
N/A
AAVXF - SRPT
45%
Loosely correlated
N/A
BHVN - SRPT
39%
Loosely correlated
+8.89%
IMVT - SRPT
38%
Loosely correlated
+0.81%
ACLX - SRPT
37%
Loosely correlated
+1.28%
More